Cognition Therapeutics CEO Issues Letter to Shareholders

Core Insights - Cognition Therapeutics is making significant advancements in developing treatments for neurodegenerative diseases, particularly focusing on zervimesine (CT1812) for dementia with Lewy bodies (DLB) and Alzheimer's disease [2][4][5] Company Progress - The company has reported strong results from the Phase 2 SHIMMER trial for zervimesine in DLB, showing favorable impacts across various symptom domains, particularly in neuropsychiatric inventory assessments [3][5] - The Phase 2 START study, which includes 545 participants with mild cognitive impairment (MCI) and early Alzheimer's disease, is fully enrolled and expected to provide data readouts in the second half of 2027 [7] Clinical Trials and Regulatory Engagement - The FDA has aligned with the company's Phase 3 program design for zervimesine, focusing on participants with low levels of p-tau217, which is associated with a significant reduction in cognitive decline [6][5] - The company plans to meet with the FDA's Division of Psychiatry in Q2 2026 to discuss the registrational plan for zervimesine in treating DLB psychosis [4] Financial and Funding Aspects - The START trial is fully funded by an NIH grant, ensuring that costs are covered through the study's completion in 2027 [7] - Cognition Therapeutics has received nearly $200 million in grants from the National Institutes of Health and related foundations to support its research efforts [9] Future Outlook - The company expresses confidence that the achievements of 2025 will propel zervimesine closer to providing effective treatment options for patients in 2026 [8]